Bempedoic Acid Found Safe Enough to Allow Breastfeeding to Continue

Cardiovascular disease remains a leading health concern, and cholesterol management is a cornerstone of prevention. Bempedoic acid, an ATP-citrate lyase inhibitor that lowers LDL cholesterol, has gained traction as an option for patients who are statin-intolerant. For postpartum women managing elevated cholesterol, the question of whether bempedoic acid is compatible with breastfeeding is clinically important.

This entry from the National Institutes of Health's Drugs and Lactation Database (LactMed) evaluates the available evidence on bempedoic acid excretion into human breast milk. The database serves as a curated, evidence-based resource used by clinicians to guide drug safety decisions during lactation.

According to the LactMed summary, bempedoic acid and its active metabolite are excreted into breast milk in very low quantities. However, no published studies have directly documented clinical outcomes in infants who were breastfed while their mothers took bempedoic acid, leaving a meaningful evidence gap.

Despite this gap, the guidance concludes that maternal use of bempedoic acid alone is not sufficient grounds to discontinue breastfeeding. The benefits of breastfeeding are well-established, and the low drug levels detected suggest minimal risk in most cases. That said, clinicians are advised to consider alternative lipid-lowering agents for mothers nursing newborns or preterm infants, populations with immature metabolic and renal clearance systems that may be more susceptible to drug accumulation.

This recommendation reflects a broader shift in pharmacological guidance toward preserving breastfeeding unless clear evidence of harm exists. For longevity-focused clinicians, this entry highlights the importance of individualized risk-benefit analysis in managing cardiovascular health across all life stages, including the postpartum period.